Conversely, in PTCL-NOS, TET2, PLCG1, RHOA, IDH2 and DNMT3A were mutated in 14.6% (6/41), 14.6% (6/41), 7.3% (3/41), 7.3% (3/41), and 4.9% (2/41) of the cases, respectively (Figure 2). This evidence concerns the gene PLCG1 and mature T-cell and NK-cell non-Hodgkin lymphoma.